Last reviewed · How we verify
Prozac
At a glance
| Generic name | Prozac |
|---|---|
| Also known as | Prozac as anti-depression treatment |
| Sponsor | RenJi Hospital |
| Target | Equilibrative nucleoside transporter 4, 5-hydroxytryptamine receptor 6, 5-hydroxytryptamine receptor 2A |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Bipolar affective disorder, current episode depression
- Bulimia nervosa
- Depressive disorder
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Premenstrual dysphoric disorder
Common side effects
- Nausea
- Insomnia
- Headache
- Anxiety
- Nervousness
- Tremor
- Diarrhea
- Dry mouth
- Sweating
- Somnolence
- Asthenia
- Libido decreased
Key clinical trials
- The Psychiatric and Cognitive Phenotypes in Velocardiofacial Syndrome (PHASE4)
- Fluoxetine and Understanding Social Experiences (NA)
- Behavioral Activation and Medication Optimization In Older Adults Undergoing Cardiac Procedures (NA)
- National Pregnancy Registry for Psychiatric Medications
- Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) (EARLY_PHASE1)
- The Effects of Fluoxetine and/or DHEA (EARLY_PHASE1)
- Care Transition Intervention for Hospitalized Patients With Advanced Cancer (NA)
- Cellular Aging and Neurobiology of Depression Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prozac CI brief — competitive landscape report
- Prozac updates RSS · CI watch RSS
- RenJi Hospital portfolio CI